FOMX News and Press, Foamix Pharmaceuticals Ltd. From 02/18/20

REHOVOT, Israel and BRIDGEWATER, N.J., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address ...

Today, we will see why Sol-Gel Technologies ( SLGL ) is a promising small-cap dermatology pick for 2020. Company overview Sol-Gel Technologies Ltd. is a clinical-stage dermatology company focused on becoming leaders in the treatment of acne and rosacea. Sol-Gel Technologies has two inves...

REHOVOT, Israel, BRIDGEWATER, N.J. and REDWOOD CITY, Calif., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) and Menlo Therapeutics Inc. (Nasdaq: MNLO) today announced that the shareholders of Foamix and stockholders of Menlo voted to approve all shareholder and...

REHOVOT, Israel and BRIDGEWATER, N.J., Feb. 6, 2020 /PRNewswire/ -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) ("Foamix" or the "Company"), a specialty pharmaceutical company, announced today the publication of the Company's Phase 3 studies FX2016-11 and FX2016-12 (Stud...

REHOVOT, Israel, and BRIDGEWATER, N.J., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company, announced today the publication of the Company’s Phase...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

REHOVOT, Israel, and BRIDGEWATER, N.J., Jan. 17, 2020 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company, announced today that OrbiMed Advisors LLC (“OrbiMed”), a signi...

REHOVOT, Israel and BRIDGEWATER, N.J., Jan. 14, 2020 /PRNewswire/ -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) ("Foamix" or the "Company"), a specialty pharmaceutical company, today announced a coverage update for its novel AMZEEQ ™ (minocycline) topical f...

Preferred Coverage Effective Immediately on Express Scripts National Preferred, Flex, and Basic Formularies AMZEEQ is the First FDA Approved Topical Form of Minocycline for the Treatment of Moderate to Severe Acne  REHOVOT, Israel and BRIDGEWATER, N.J., Jan. 14,...

AMZEEQ is the First FDA Approved Topical Form of Minocycline and the Company’s First Commercial Launch AMZEEQ Offers Efficacy with Low Systemic Absorption List price of $485 Competitive Against Current Acne Market Leaders REHOVOT, Israel and BRIDGEWATER, N...